Literature DB >> 19393958

Gram-positive toxic shock syndromes.

Emma Lappin1, Andrew J Ferguson.   

Abstract

Toxic shock syndrome (TSS) is an acute, multi-system, toxin-mediated illness, often resulting in multi-organ failure. It represents the most fulminant expression of a spectrum of diseases caused by toxin-producing strains of Staphylococcus aureus and Streptococcus pyogenes (group A streptococcus). The importance of Gram-positive organisms as pathogens is increasing, and TSS is likely to be underdiagnosed in patients with staphylococcal or group A streptococcal infection who present with shock. TSS results from the ability of bacterial toxins to act as superantigens, stimulating immune-cell expansion and rampant cytokine expression in a manner that bypasses normal MHC-restricted antigen processing. A repetitive cycle of cell stimulation and cytokine release results in a cytokine avalanche that causes tissue damage, disseminated intravascular coagulation, and organ dysfunction. Specific therapy focuses on early identification of the illness, source control, and administration on antimicrobial agents including drugs capable of suppressing toxin production (eg, clindamycin, linezolid). Intravenous immunoglobulin has the potential to neutralise superantigen and to mitigate subsequent tissue damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393958     DOI: 10.1016/S1473-3099(09)70066-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  109 in total

1.  A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes.

Authors:  Ningyan Wang; Daiva M Mattis; Eric J Sundberg; Patrick M Schlievert; David M Kranz
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

2.  Control of the Staphylococcus aureus toxic shock tst promoter by the global regulator SarA.

Authors:  Diego O Andrey; Adriana Renzoni; Antoinette Monod; Daniel P Lew; Ambrose L Cheung; William L Kelley
Journal:  J Bacteriol       Date:  2010-09-24       Impact factor: 3.490

3.  GET_HOMOLOGUES, a versatile software package for scalable and robust microbial pangenome analysis.

Authors:  Bruno Contreras-Moreira; Pablo Vinuesa
Journal:  Appl Environ Microbiol       Date:  2013-10-04       Impact factor: 4.792

4.  Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy.

Authors:  Nolwenn Le Saché; Mickael Afanetti; Kumaran Deiva; Laurent Chevret; Pierre Tissières
Journal:  J Neurol       Date:  2013-09-20       Impact factor: 4.849

Review 5.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

6.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

7.  Travel-related Streptococcal toxic shock syndrome caused by emm type 78 Streptococcus pyogenes.

Authors:  Dennis Tappe; Marco H Schulze; Mark van der Linden; Uwe Ziegler; Andreas Müller; August Stich
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

8.  Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yosuke Harada; Koichi Yamada; Yohei Migiyama; Yoshitomo Morinaga; Hiroo Hasegawa; Koichi Izumikawa; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors.

Authors:  Mariko Honda-Ogawa; Taiji Ogawa; Yutaka Terao; Tomoko Sumitomo; Masanobu Nakata; Kazunori Ikebe; Yoshinobu Maeda; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

10.  Group G streptococcal sepsis, septic arthritis and myositis in a patient with severe oral ulcerations.

Authors:  Wu Deng; Laurie Farricielli
Journal:  BMJ Case Rep       Date:  2014-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.